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Abstract
Background: Inpatient palliative care is important for patients with terminal pancreatic cancer. However, the
differences between inpatient palliative care and acute hospital care for inpatients with pancreatic cancer have not
been explored in a population-based study.
Methods: This population-based nationwide study was conducted using data from the Taiwan National Health
Insurance database to analyze the differences between inpatient palliative care and acute hospital care for
inpatients with pancreatic cancer. We identified 854 patients with terminal pancreatic cancer, who had received
in-hospital end-of-life care between January 2003 and December 2006. These patients were then sub-divided
and matched 1:1 (using propensity score matching) according to whether they received inpatient palliative care
(n = 276) or acute hospital care (n = 276). These groups were subsequently compared to evaluate any differences in
the use of aggressive procedures, prescribed medications, and medical costs.
Results: Inpatient palliative care was typically provided by family physicians (39 %) and oncologists (25 %), while
acute hospital care was typically provided by oncologists (29 %) and gastroenterologists (24 %). The inpatient
palliative care group used natural opium alkaloids significantly more frequently than the acute hospital care
group (84.4 % vs. 56.5 %, respectively; P < 0.001). The inpatient palliative care group also had shorter hospital stays
(10.6 ± 11.1 days vs. 20.6 ± 16.3 days, respectively; P < 0.001), fewer aggressive procedures, and lower medical costs
(both, P < 0.005).
Conclusions: Compared to patients in acute hospital wards, patients with pancreatic cancer in inpatient palliative
care units received more frequent pain control treatments, underwent fewer aggressive procedures, and incurred
lower medical costs. Therefore, inpatient palliative care should be considered a viable option for patients with
terminal pancreatic cancer.
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Background
Pancreatic cancer is one of the worldwide leading causes
of cancer-related death [1], and pancreatic cancer is the
fourth most common type of solid tumor in the United
States [1]. Unfortunately, most patients with pancreatic
cancer are in the advanced stages, and have a median
expected survival period of <8 months [2]. In addition,
patients with terminal pancreatic cancer frequently suf-
fer from weight loss, jaundice, loss of appetite, nausea,
vomiting, abdominal pain, back pain, cachexia, esopha-
geal variceal bleeding, and ascites [2]. Therefore, symp-
tomatic treatment is important for relieving the
discomfort that is experienced by these patients.
Hospice care aims to provide supportive care to
patients who are in the final stage of a terminal illness
[3]. Supportive care is the treatment given to prevent,
control, or relieve complications and side effects and to
improve the patient's comfort and quality of life [4].
Therefore, hospice care focuses on improving the pa-
tient’s comfort and quality of life, rather than achieving a
cure for their condition. Hospice programs typically use
a multidisciplinary approach, which includes the services
of doctors, nurses, social workers, and clergy, in order to
offer holistic care to patients. Based on this comprehen-
sive care, it has been reported that patients who receive
hospice care experience a better quality of life, compared
to patients with similar conditions who receive conven-
tional care [5].
Palliative care is an approach that improves the quality
of life of patients and their families facing the problems
that are associated with life-threatening illness, through
the prevention and relief of suffering by early identifica-
tion and impeccable assessment and treatment of pain
and other physical, psychosocial, and spiritual problems
[6]. Inpatient palliative care in Taiwan is covered by
National Health Insurance (NHI) programs, and is of-
fered by many medical centers (medical facilities that are
larger than regional or district hospitals) or school-
affiliated hospitals. However, only a small percentage of
terminally ill patients ultimately select inpatient pallia-
tive care [7, 8], and the rate of inpatient palliative care
use was 12.3 % among patients with cancer who died be-
tween 2000 and 2004 [8]. Furthermore, although the
trend of inpatient palliative care use increased from
5.5 % in 2000 to 15.4 % in 2004, the rate of Taiwanese
inpatient palliative care use remains far below the rates
in Western countries [7–10]. This relatively low usage
may be due to individual misconceptions, physician pref-
erences, and/or cultural concerns [9, 10]. A previous
study in a Taiwanese inpatient palliative care unit re-
ported that inpatients with advanced cancer in inpatient
palliative care units had a shorter length of stay, com-
pared to inpatients who were treated at acute hospital
wards [11]. Nevertheless, there are no studies that have
performed a comprehensive, nationwide comparison of
inpatient palliative care and acute hospital care for pa-
tients with pancreatic cancer. Therefore, using informa-
tion from Taiwan’s NHI database, we aimed to compare
the patient characteristics, medical procedures, prescrip-
tions, and medical costs for patients with pancreatic can-
cer who received inpatient palliative care or acute




Taiwan’s NHI program is a compulsory universal health
insurance program (approximately 97 % of all residents
were enrolled in 2004), which offers comprehensive
medical care coverage to all residents. The NHI dataset,
which is compiled and managed by the National Health
Research Institutes and publicly available to researchers,
consists of comprehensive healthcare information from
all NHI beneficiaries [12].
In this study, we obtained records, including medical
order files and hospital administration files, from all in-
patient beneficiaries who made a claim between January
2003 and December 2006. Using these records, we ex-
tracted anonymized inpatient identification numbers,
dates of admission and discharge, 1 major and 4 minor
disease ICD-9-CM diagnoses (International Classifica-
tion of Diseases, 9th Revision, Clinical Modification),
examination costs, procedures, surgeries, prescribed
drugs, and special medical materials that were used dur-
ing the admission. The patients’ medical order files also
contained details regarding the doctors’ orders and labora-
tory tests. The accreditation level of each hospital (i.e.,
medical center, regional hospital, or district hospital) was
determined using the hospital’s administration files. A
complete database of the coding numbers, which identifies
the prescribed drugs and procedures, were obtained from
the NHI website [13].
This study was conducted in accordance with the
Helsinki Declaration, and was approved by the institu-
tional review board of National Yang-Ming University
(approval no. 1000046).
Study population
In this study, we identified 854 pancreatic cancer pa-
tients who were admitted and died in-hospital between
January 2003 and December 2006. Pancreatic cancer was
defined using an ICD-9-CM compatible code (157) from
the Registry for Catastrophic Illness Patient database,
which is a separate subsection of the NHI database.
Most patients who are diagnosed with cancer sign up for
a Catastrophic Illness Card in Taiwan, and these card-
holders are exempt from cost-sharing under the NHI
program. The effects of comorbidities were estimated
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using the Charlson comorbidity index [14]. Propensity
score matching was performed to minimize the potential
influence of selection bias, whereby logistic regression
was used to create a propensity score for the inpatient
palliative care and acute hospital care groups [15]. The
covariates that we examined included patient character-
istics (age and sex), Charlson comorbidity index, hospital
location, and hospital accreditation level. One-to-one
matching was subsequently performed for the two pa-
tients groups, using the nearest-neighbor matching
method.
Statistical analysis
Data linkage, processing, and computation were per-
formed using Microsoft Structured Query Language Ser-
ver 2008 (Microsoft Corp., Redmond, WA, USA), and
SPSS software (version 21.0, SPSS Inc., Chicago, IL,
USA) was used to analyze the data for descriptive and
inferential statistics. The Mann-Whitney U test was used
to analyze numerical data between the groups, and the
chi-square test was used to compare categorical vari-
ables. A generalized linear model with gamma distribu-
tion and a log link function was used to analyze medical
costs, which are typically right-skewed [16]. Differences
were considered statistically significant at a P-value of
<0.05. All data were presented as mean ± standard devi-
ation or number (%) as appropriate.
Results
Baseline characteristics
Among the 854 terminally ill patients with pancreatic
cancer that we identified, 276 (32 %) patients were
treated in inpatient palliative care units (173 men and
103 women; mean age = 68.6 years) and 578 (68 %) were
treated at acute hospital wards (354 men and 224
women; mean age = 67.5 years) (Table 1). All physicians
who treated these patients had passed standardized hos-
pice specialist training courses in Taiwan. The inpatient
palliative care group was typically managed by family
physicians (39 %) and oncologists (25 %), whereas the
acute hospital care group was typically managed by in-
ternal medicine physicians (39 %, P < 0.001), who were
generally gastroenterologists (24 %). Significant differ-
ences between the palliative care and pre-matched acute
care patients were observed for the hospital accredit-
ation level (P = 0.03) and hospital regional location (P =
0.021). The Charlson comorbidity indices were not sig-
nificantly different between the two groups, although the
length of hospital stay was significantly shorter for the
inpatient palliative care group (10.6 ± 11.1 days vs. 20.6
± 16.7 days, respectively; P < 0.001). After one-to-one
propensity score matching, 276 matched controls were
selected, and we found that the baseline patient charac-
teristics in the two groups were similar (Table 1).
Aggressive procedures
The aggressive procedures that were used to treat the in-
patient palliative care group and the matched acute hos-
pital care group are shown in Table 2. The patients in the
acute hospital care group underwent significantly more
aggressive procedures, including urinary catheterization,
nasogastric tube feeding, central venous catheter insertion,
intensive care unit admission, endotracheal intubation, ab-
dominal drainage, cardiopulmonary resuscitation, total
parenteral nutrition, percutaneous transhepatic cholangi-
ography and drainage, chest tapping or intubation, and
defibrillation/cardioversion (all P < 0.001). Only one pa-
tient in the inpatient palliative care group underwent an
aggressive procedure (hemodialysis).
Drug prescription patterns
The prescription patterns for both care groups are
shown in Table 3, according to their Anatomical Thera-
peutic Chemical classification. In the inpatient palliative
care group, the most commonly prescribed medication
was natural opium alkaloids (84.4 %), followed by solu-
tions that affect electrolyte balance (80.1 %), propulsives
(55.1 %), contact laxatives (52.9 %), and benzodiazepine
derivatives (48.2 %). In the matched acute hospital care
group, the most commonly prescribed medication was
solutions that affect electrolyte balance (97.1 %), followed
by solutions for parenteral nutrition (80.8 %), propulsives
(72.5 %), plain sulfonamide diuretics (71.7 %), and electro-
lyte solutions (66.7 %). Compared to the acute hospital
care group, the inpatient palliative care patients more fre-
quently received natural opium alkaloids (84.4 % vs.
56.5 %; P < 0.001) and benzodiazepine derivatives (48.2 %
vs. 26.8 %; P < 0.001), although they less frequently re-
ceived cephalosporins (32.2 % vs. 60.5 %; P < 0.001)
and adrenergic or dopaminergic agents (5.8 % vs.
52.9 %; P < 0.001).
Medical costs
A comparison of the medical costs for both care groups
is shown in Table 4. The combined daily medical costs
were significantly lower for the inpatient palliative care
group, compared to those for the acute hospital care
group (adjusted mean = 107 US [101–113] dollars/day, vs.
253 [210–308] US dollars/day, respectively; P < 0.001). In
addition, all daily medical cost categories were signifi-
cantly higher in the acute hospital care group, including
diagnoses, laboratory examinations, radiologic exami-
nations, therapies, medications, and hemodialysis (all
P < 0.005).
Discussion
In this study, we collected comprehensive data from the
NHI records of patients with terminal pancreatic cancer,
and used these data to compare inpatient palliative care
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and acute hospital care. Our analysis revealed that the ma-
jority of patients with pancreatic cancer were men and
had been hospitalized in medical centers. Furthermore,
most patients were treated in acute hospital wards. In the
inpatient palliative care group, approximately 40 % of pa-
tients were treated by family physicians, and these patients
had shorter hospital stays, fewer aggressive procedures,
and lower medical costs. Furthermore, these patients were
prescribed more natural opium alkaloids and benzodi-
azepine derivatives, compared to the acute hospital care
inpatients. However, given the relatively short hospital
stays, we could not perform a detailed analysis of the du-
rations for all medical procedures.
In Taiwan, the only available forms of hospice care are
inpatient palliative care and home palliative care [17],
and there were 50 hospital-based inpatient palliative care
units and 69 home palliative care teams in April 2015
[18]. The palliative care teams only offer consultations
for patients in acute hospital wards. The physicians in
acute hospital wards are responsible for all care-related
decisions for patients in acute hospital wards. It has
been estimated that 13,000 patients with cancer receive
Table 1 Baseline characteristics of terminal pancreatic cancer patients according to end-of-life care
Inpatient palliative care Acute hospital care
Characteristics Pre-matched Post-matched
n (%) n (%) P n (%) P
Number of patients 276 (100) 578 (100) 276 (100)
Age (years; mean ± SD) 68.6 ± 13.4 67.5 ± 12.8 0.265 68.5 ± 12.4 0.953
Sex 0.687 0.535
Male 173 (63) 354 (61) 180 (65)
Female 103 (37) 224 (39) 96 (35)
Physicians’ specialty <0.001 <0.001
Family medicine 108 (39) 38 (7) 24 (7)
Oncology 69 (25) 174 (30) 77 (29)
Internal medicine 64 (23) 226 (39) 104 (43)
General 57 (21) 64 (11) 28 (10)
Gastroenterology 3 (1) 138 (24) 65 (24)
Cardiology 0 (0) 3 (1) 2 (0.7)
Chest medicine 0 (0) 14 (2) 8 (3)
Nephrology 1 (0.4) 2 (0.3) 0 (0)
Endocrinology 0 (0) 4 (0.7) 1 (0.4)
Infection 3 (1) 1 (0.2) 0 (0)
Radiation oncology 25 (9) 17 (3) 6 (2)
Surgery 0 (0) 113 (20) 57 (18)
Neurology 9 (3) 6 (1) 3 (1)
Others 1 (0.4) 4 (0.7) 4 (1)
Accreditation level of hospital 0.030 0.304
Medical centers 161 (58) 316 (55) 156 (57)
Regional hospitals 73 (26) 199 (34) 87 (32)
District hospitals 42 (15) 63 (11) 33 (12)
Region of hospital 0.021 0.668
North 171 (62) 401 (69) 171 (62)
Central 20 (7) 49 (8) 25 (9)
South 75 (27) 120 (21) 74 (27)
East 10 (4) 8 (1) 6 (2)
Charlson comorbidity index (mean ± SD) 6.8 ± 6.5 6.7 ± 6.5 0.798 6.9 ± 2.8 0.564
Length of hospital stay (day, mean ± SD) 10.6 ± 11.1 20.6 ± 16.7 <0.001 20.6 ± 16.3 <0.001
SD standard deviation
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these services each year in Taiwan [19], and inpatient pal-
liative care is available and fully accessible to all healthcare
beneficiaries, to whom it is offered at all medical centers
and in select regional hospitals, although it is rarely of-
fered in district hospitals. Furthermore, Taiwanese patients
with pancreatic cancer are frequently referred to medical
centers, which have a full complement of diagnostic facil-
ities and greater treatment capabilities [20]. These patients
can then be transferred to the inpatient palliative care
units or acute hospital wards when they become termin-
ally ill. Although sophisticated medical services are rarely
used for patients who receive inpatient palliative care or
acute hospital care, it is more convenient for patients at
medical centers to access these services, compared to in-
patients at regional or district hospital. Therefore, patients
with terminal pancreatic cancer are more frequently
admitted to medical centers, rather than to regional or
district hospitals.
Inpatient palliative care is not widely used in Taiwan,
and we found that the majority of terminally ill patients
with pancreatic cancer elected to receive end-of-life care
at acute hospital wards. Several factors might influence
the decision to not select inpatient palliative care, such
as physician preferences and referral practices, cultural
concerns, individual patient choices and circumstances,
and public or professional awareness of the benefits of
inpatient palliative care [9, 10, 21, 22]. Unfortunately, in
Taiwan, inpatient palliative care units are associated with
a negative image (i.e., ‘death wards’), and a strong sense
of familial obligation leads families to provide in-home
care to sick family members. In addition, caregivers and
family members typically prefer life-sustaining treatment
Table 2 Aggressive procedures used to treat terminal pancreatic cancer patients according to end-of-life care
Procedures Inpatient palliative care Acute hospital care P
(n = 276) (n = 276)
n % n %
Urinary catheterization 0 0 156 56.5 <0.001
Nasogastric tube feeding 0 0 86 31.2 <0.001
Central venous catheter insertion 0 0 77 27.9 <0.001
Intensive care unit admission 0 0 57 20.7 <0.001
Endotracheal intubation 0 0 49 17.8 <0.001
Abdominal drainage 0 0 33 12.0 <0.001
Cardiopulmonary resuscitation 0 0 28 10.1 <0.001
Total parenteral nutrition 0 0 25 9.1 <0.001
Percutaneous transhepatic cholangiography and drainage 0 0 23 8.3 <0.001
Chest tapping or intubation 0 0 15 5.4 <0.001
Defibrillation/cardioversion 0 0 9 3.3 <0.001
Hemodialysis 1 0.4 7 2.5 0.068
Epinephrine injection 0 0 4 1.4 0.124
Table 3 Medications used to treat terminal pancreatic patients according to end-of-life care
Ranking Inpatient palliative care (n = 276) Acute hospital care (n = 276)
Drug class (ATC code) n % Drug class (ATC code) n %
1 Natural opium alkaloids (N02AA) 233 84.4 Solutions affecting the electrolyte balance (B05BB) 268 97.1
2 Solutions affecting the electrolyte balance (B05BB) 221 80.1 Solutions for parenteral nutrition (B05BA) 223 80.8
3 Propulsives (A03FA) 152 55.1 Propulsives (A03FA) 200 72.5
4 Contact laxatives (A06AB) 146 52.9 Plain sulfonamide diuretics (C03CA) 198 71.7
5 Benzodiazepine derivatives (N05CD) 133 48.2 Electrolyte solutions (B05XA) 184 66.7
6 Solutions for parenteral nutrition (B05BA) 124 44.9 Contact laxatives (A06AB) 167 60.5
7 Glucocorticoids (H02AB) 123 44.6 Cephalosporins (J01DA) 167 60.5
8 Plain sulfonamide diuretics (C03CA) 118 42.8 Phenylpiperidine derivatives opioids (N02AB) 159 57.6
9 Butyrophenone derivatives antipsychotics (N05AD) 111 40.2 Natural opium alkaloids (N02AA) 156 56.5
10 Magnesium compounds (A02AA) 108 39.1 Adrenergic and dopaminergic agents (C01CA) 146 52.9
ATC Anatomical Therapeutic Chemical
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for terminally ill patients, and some physicians prefer
not to discuss end-of-life issues with their patients [23].
Therefore, these factors may motivate Taiwanese pa-
tients and their families to elect for end-of-life care in
acute hospital wards, rather than in inpatient palliative
care units.
The basic philosophical tenets of end-of-life care have
been rooted in the recognition of an individual’s per-
sonal dignity. Therefore, the most common treatment
objectives for inpatient palliative care include helping
patients die with dignity, alleviating pain and suffering,
controlling symptoms, and using less aggressive therap-
ies [10, 24, 25]. In this study, we found that 84.4 % of
the inpatient palliative care patients were prescribed
natural opium alkaloids, which is noticeably higher
than the prescription rate (72.7 %) in a previous study
of inpatient palliative care for patients with hepatocel-
lular carcinoma [17]. Furthermore, only 56.5 % of the
patients in the acute hospital care group were pre-
scribed natural opium alkaloids. However, among pa-
tients with pancreatic cancer, pain is a major source of
distress [2], and adequate pain control is the primary
priority in terminally ill cases, which may partially ex-
plain why the patients in the inpatient palliative care
group more frequently received benzodiazepine deriva-
tives (48.2 % vs. 26.8 % in the acute hospital care
group). These drugs are an important adjuvant to con-
trol pain, and can help treat concomitant psychological
disturbances, such as insomnia, anxiety, and depres-
sion, according to the World Health Organization’s
guide for cancer pain relief [26]. Moreover, the pa-
tients in the inpatient palliative care group used fewer
cephalosporins (32.2 % vs. 60.5 %, respectively) and
adrenergic or dopaminergic agents (5.8 % vs. 52.9 %,
respectively), which is likely because these treatments
are typically futile in patients with terminal pancreatic
cancer [27].
There were 4,686 deaths due to pancreatic cancer from
2003 to 2006 [28]. However, home palliative care is widely
used in Taiwan [18], and many patients were discharged,
against their physician’s advice, when they were dying
[29]. Thus, only 854 patients with terminal pancreatic can-
cer who died in-hospital were included in this study.
Nevertheless, our findings indicated that there were sig-
nificant differences between inpatient palliative care and
acute hospital care for patients with terminal pancreatic
cancer.
Although we found that inpatient palliative care re-
sulted in significantly shorter hospital stays, there is
controversy in the existing literature regarding whether
inpatient palliative care leads to shorter or longer hos-
pital stays [7, 11]. In our study, patients in the pallia-
tive care units used fewer aggressive procedures, which
may lead to shorter lifespans and shorter hospital
stays. However, we also found that inpatient palliative
care resulted in lower per-person or daily medical
costs, compared to acute hospital care. These findings
may be attributable to the patients’ poor general condi-
tions after termination of anticancer treatment, and
their rapidly growing pancreatic tumors. Moreover, the
treatment of patients’ poor general condition and
symptoms of pancreatic cancer are challenging, and
typically empirical, in inpatient palliative care units.
Therefore, increasing the use of solutions that affect
electrolyte balance, solutions for parenteral nutrition,
propulsives, electrolyte solutions, cephalosporins, and
adrenergic or dopaminergic agents may prolong the
lives of some patients. However, prolonging the lives of
terminally ill patients, such as the patients in our
study, will inevitably prolong their suffering. Therefore,
as we found that inpatient palliative care cost less than
acute hospital care, the cost-benefit ratio of acute hos-
pital care should be subjected to further evaluation
[25, 30, 31]. Furthermore, we only evaluated patients
who were treated during 2003–2006, and the number
of Taiwanese inpatient palliative care units has in-
creased from 26 in 2004 to 53 in 2015 [32]. Therefore,
inpatient palliative care has become more accepted by
the general public, which further supports its consider-
ation during end-of-life decision-making.
Table 4 Medical costs for terminal pancreatic cancer patients according to end-of-life care
Items Inpatient palliative care (N = 276) Acute hospital care (N = 276) P*
Adjusted mean 95 % CI Adjusted mean 95 % CI
Diagnosis costs 11.5 11.2–12.0 12.9 12.3–13.5 0.001
Laboratory examination costs 5.9 4.9–6.9 26.8 22.8–33.4 <0.001
Radiologic examination costs 1.1 0.7–1.6 16.9 9.6–28.0 <0.001
Therapeutic costs 16.7 15.0–18.4 25.7 22.1–29.9 <0.001
Medication costs 25.4 22.4–29.6 61.8 54.8–68.9 <0.001
Hemodialysis costs 2.5 1.2–4.2 22.7 12.2–38.3 0.005
Total medical costs 107 101–113 253 210–308 <0.001
All values are reported as US dollars/day
*Analyzed using a generalized linear model with gamma distribution and log link function. 95 % CI: 95 % confidence interval
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The major strength of this study was its nationwide
population-based design, which included a relatively large
number of patients with pancreatic cancer. Furthermore,
this design facilitated a comprehensive evaluation of the
medical behaviors and costs that were associated with in-
patient palliative care and acute hospital care. Therefore,
the findings of our study provide epidemiological evidence
that inpatient palliative care provides a greater amount of
palliative care for patients with terminally ill pancreatic
cancer and is less expensive than acute hospital care.
Thus, these findings may provide the basis for changing
traditional Taiwanese perceptions regarding inpatient pal-
liative care, and for promoting end-of-life inpatient pallia-
tive care for patients with pancreatic cancer.
This study has several limitations that should be consid-
ered when interpreting our findings. First, we could not
obtain data regarding the patients’ educational and socio-
economic status, the preferences of the patients and their
caregivers, patient life expectancies, and the attitudes of
physicians toward inpatient palliative care. However, al-
though only a limited number of covariates were included
in the logistic regression model, our propensity-score
matching at the patient level provided comparable base-
line characteristics between the two groups, which may
have eliminated some selection biases. Second, although
fewer aggressive procedures and a lower cost burden are
desirable factors, such as those observed in the inpatient
palliative care group, we were unable to obtain data re-
garding the patients’ symptom burdens, pain scores, or
quality of life measures. Therefore, future research should
incorporate quality of life measures to advance our know-
ledge regarding the effects of inpatient palliative care.
Third, eligible patients receive a fixed daily payment from
Taiwan NHI for inpatient palliative care [33], and this pay-
ment may influence the observed differences in the use of
medications, aggressive procedures, and incurred costs be-
tween the two groups.
Conclusions
Inpatient palliative care units provided patients with pan-
creatic cancer more frequent pain control treatments,
fewer aggressive procedures, and lower medical costs,
compared to patients in acute hospital wards. Therefore,
inpatient palliative care should be considered a viable op-
tion for treating patients with terminal pancreatic cancer.
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